Deep Vein Thrombosis News and Research

RSS

Deep vein thrombosis, or DVT, is a blood clot that forms in a vein deep in the body. Most deep vein clots occur in the lower leg or thigh. If the vein swells, the condition is called thrombophlebitis. A deep vein thrombosis can break loose and cause a serious problem in the lung, called a pulmonary embolism, or a heart attack or stroke.

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

Study may pave for effective treatments for blood clotting disorders

A key protein that causes the blood to clot is produced by blood vessels in the lungs and not just the liver, according to new research published today in the journal PLoS One, led by scientists at Imperial College London.

11 Feb 2010

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

3 Feb 2010

Multiple ultrasounds may not be necessary for diagnosing DVT in some low-risk patients

An analysis of previous studies suggests that for patients with a suspected blood clot in a deep vein of a leg, withholding anticoagulation therapy after a negative whole-leg compression ultrasound is associated with a low risk of developing a blood clot during the subsequent 3 months, suggesting that multiple ultrasounds may not be necessary for some low-risk patients, according to an article in the February 3 issue of JAMA.

3 Feb 2010

Three hospitals selected as recipients of the 2009 DVTeamCare Hospital Award

The North American Thrombosis Forum (NATF), in coordination with Eisai Inc., announced today that three hospitals have been selected as recipients of the 2009 DVTeamCare Hospital Award. This new award was established by Eisai to recognize hospitals that have made a significant commitment to preventing deep vein thrombosis (DVT) and its potentially fatal complications, including pulmonary embolism (PE).

20 Jan 2010

IPMT procedure can benefit patients with acute deep vein thrombosis

Patients with acute deep vein thrombosis (DVT) develop potentially dangerous blood clots and can suffer severe leg pain and swelling. Doctors with Virginia Interventional & Vascular Associates (VIVA) report success over the past two years in treating acute DVT patients with a procedure called isolated pharmacomechanical thrombolysis (IPMT), which destroys clots much faster than traditional therapies.

7 Jan 2010

Maine-based EMHS recognized for creating system-wide culture of safety

A poor economy in a rural area might seem like overwhelming obstacles to creating a sophisticated culture of safety in a health care system that serves the largest aging population in the country, but leaders at Eastern Maine Healthcare Systems (EMHS) beat those odds in 2009.

14 Dec 2009

J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), announced today that results from the Phase III EINSTEIN-Extension (EXT) clinical trial of the novel oral anticoagulant rivaroxaban showed a significant reduction in the risk of recurrent symptomatic venous thromboembolism (VTE), compared to placebo, in patients who have been treated for a previous deep vein thrombosis (DVT) or pulmonary embolism (PE).

7 Dec 2009

Dabigatran etexilate offers effective therapy to prevent recurrent VTE

Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.

6 Dec 2009

Risk of having a potentially fatal blood clot after surgery is higher, finds research

The risk of having a potentially fatal blood clot after surgery is higher and lasts for longer than had previously been thought, concludes new research published on bmj.com today.

4 Dec 2009

ASH Annual Meeting to showcase latest research and treatments for blood disorders

The American Society of Hematology (ASH), the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. The meeting will showcase the latest research and treatments for blood disorders.

2 Dec 2009

Boehringer Ingelheim to announce positive results from its RE-COVER study

Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.

2 Dec 2009

Catheter-directed therapy: First-line treatment option for massive pulmonary embolism

Catheter-directed therapy or catheter-directed thrombolysis-an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs-saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology.

12 Nov 2009

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. The findings will be published online on Nov. 10, 2009 in the Journal of the National Cancer Institute (ahead of the Dec. 2, 2009 print edition).

11 Nov 2009

ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

4 Nov 2009

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

Broadlane's partnership with CTC helps to deliver 24% average savings to its clients

Broadlane has delivered an average savings of 24 percent to healthcare clients by partnering with Compression Therapy Concepts (CTC), a certified, small-business, woman-owned diversity supplier of Deep Vein Thrombosis (DVT) prevention products. The relationship has also increased CTC’s market share within the Broadlane client base from less than 1 percent to approximately 60 percent.

21 Oct 2009

New device minimizes brain damage by speeding the delivery of post-stroke countermeasures

A new device from NeuroInterventions, Inc., is designed to minimize brain damage by dramatically speeding the delivery of post-stroke countermeasures.

12 Oct 2009

ACS NSQIP recognizes Baylor Dallas for achieving exemplary outcomes for surgical patient care

Baylor University Medical Center at Dallas has been recognized as one of 25 hospitals in the nation achieving exemplary outcomes for surgical patient care.

1 Oct 2009

African Americans at higher risk of developing potentially deadly DVT and PE than other ethnic populations

Speaking at the Venous Disease Coalition (VDC) Annual Meeting today, Dr. Garth Graham from the Office of Minority Health at the Department of Health and Human Services followed up on last year's Surgeon General's Call to Action by focusing attention on the African American population which is at significantly increased risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

18 Sep 2009